Now that the Graham-Cassidy bill has failed, here’s what healthcare executives should do to plan for 2018.
Now that the Graham-Cassidy bill has failed, here’s what healthcare executives should do to plan for 2018.
1. Recalibrate product portfolio, networks and service areas for 2019.
Steele
“Soon after open enrollment is finished, plans will be planning for 2019,” says John Steele, partner at HealthScape Advisors consulting firm. “Insurers should take a close look at how product selection and competitive landscape changes are impacting 2018 enrollment and infuse into their 2019 planning.”
2. Offer practical insight to policymakers about what makes sense.
“Managed care executives are where the rubber literally meets the road, but they need to separate out Medicaid expansion issues from the ACA market products,” says Jay Wolfson, DrPH, JD, distinguished service professor, Public Health, Medicine and Pharmacy, and senior associate dean, Morsani College of Medicine, University of South Florida Health. “If the Administration permanently elects to not enforce the individual ‘tax’ for not acquiring insurance and further elects to limit or discontinue subsidies-and there is a legal basis for that determination-then elements of the ACA will become increasingly dysfunctional. This will not only harm beneficiaries who cannot afford to use, let alone policies-but providers and insurers who have planned to rely on the premium payments and service revenue.”
Wolfson
3. Set business plans for the next two to three years.
Bob Atlas, a strategic advisor and president of consulting firm EBG Advisors, Inc., calls this time a “moment of relative clarity in public policy.”
“Choose targets that suit your company’s core competencies rather than leap into unfamiliar realms,” he says. “But try to diversify your portfolio to protect against political risks, not just underwriting risks.”
4. Focus on enhancing population health and reducing cost of care.
“Regardless of any action in D.C., the cost of healthcare continues to rise across all segments,” Steele says. “Most of the financial turnaround in the industry has been through pricing. Going forward there will be limits to how much insurers can continue to price into their products due to affordability.”
5. Increase exposure to Medicare Advantage.
Atlas
“Demographic trends, changes to Medigap in 2020 and reimbursement structure makes Medicare attractive relative to other market segments,” Steele says.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
Extending the Capabilities of the EHR Through Automation
August 2nd 2023Welcome back to another episode of "Tuning In to the C-Suite," where Briana Contreras, an editor of Managed Healthcare Executive, had the pleasure of chatting with Cindy Gaines, chief clinical transformation officer at Lumeon.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More
Drugs to Watch: Mental Health Conditions
April 11th 2024The FDA is reviewing two novel therapies: a psychedelic-assisted therapy for PTSD with a target action date of Aug. 11, 2024, and therapy for schizophrenia that does not directly block dopamine receptors with an action date of Sept. 26, 2024.
Read More